{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T08:29:57Z","timestamp":1776673797192,"version":"3.51.2"},"reference-count":125,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T00:00:00Z","timestamp":1776556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: In the last decade, a surge of advancements in and approvals of immunotherapies has revolutionized the treatment of non-small-cell lung cancer (NSCLC). Even as an increasing number of immune checkpoint inhibitors and antibody\u2013drug conjugates gained FDA approval for the remarkable response and durable remission they imparted to some patients, persistent challenges of primary and acquired resistance, imperfect predictive biomarkers, and toxicity remain. Methods: This review identifies and summarizes the most significant emerging clinical data being reported for immunotherapies in NSCLC. Results: We found that the most recent clinical trials are centered on antibody\u2013drug conjugates, bispecific and multispecific antibodies, cellular therapies, and immunocytokines, while other ongoing trials continue to explore new monoclonal antibodies as well as a variety of immunotherapy modalities. Conclusions: Immunotherapy in NSCLC remains an area of rapid advancement, with the potential for further improvements in safety and efficacy as monotherapy and in multimodal approaches.<\/jats:p>","DOI":"10.3390\/cancers18081291","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T07:15:08Z","timestamp":1776669308000},"page":"1291","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging Immunotherapy and Antibody-Derived Therapeutics for the Treatment of Advanced Non-Small-Cell Lung Cancer: A Review"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2572-7711","authenticated-orcid":false,"given":"Alicia Yunxin","family":"Hou","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic, Jacksonville, FL 32224, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina","family":"Elantably","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine, Mayo Clinic, Jacksonville, FL 32066, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rami","family":"Manochakian","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine, Mayo Clinic, Jacksonville, FL 32066, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vamsidhar","family":"Velcheti","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine, Mayo Clinic, Jacksonville, FL 32066, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenduo","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine, Mayo Clinic, Jacksonville, FL 32066, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3214-2658","authenticated-orcid":false,"given":"Yujie","family":"Zhao","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine, Mayo Clinic, Jacksonville, FL 32066, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanyan","family":"Lou","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine, Mayo Clinic, Jacksonville, FL 32066, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,19]]},"reference":[{"key":"ref_1","first-page":"e70043","article-title":"Cancer Statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","first-page":"229","article-title":"Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","first-page":"50","article-title":"Screening for Lung Cancer: 2023 Guideline Update from the American Cancer Society","volume":"74","author":"Wolf","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","first-page":"308","article-title":"Cancer Treatment and Survivorship Statistics, 2025","volume":"75","author":"Wagle","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1634\/theoncologist.2015-0507","article-title":"FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer with Progression on or After Platinum-Based Chemotherapy","volume":"21","author":"Kazandjian","year":"2016","journal-title":"Oncologist"},{"key":"ref_6","unstructured":"(2026, March 31). Pembrolizumab (KEYTRUDA) Checkpoint Inhibitor, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/pembrolizumab-keytruda-checkpoint-inhibitor."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1634\/theoncologist.2015-0498","article-title":"FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1","volume":"21","author":"Sul","year":"2016","journal-title":"Oncologist"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.1158\/1078-0432.CCR-17-0540","article-title":"U.S. Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non\u2013Small Cell Lung Cancer","volume":"23","author":"Weinstock","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_9","unstructured":"(2026, March 31). Pembrolizumab (Keytruda) 5-10-2017, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/pembrolizumab-keytruda-5-10-2017."},{"key":"ref_10","unstructured":"(2026, March 31). FDA Approves Pembrolizumab in Combination with Chemotherapy for First-Line Treatment of Metastatic Squamous NSCLC, Available online: https:\/\/www.fda.gov\/drugs\/fda-approves-pembrolizumab-combination-chemotherapy-first-line-treatment-metastatic-squamous-nsclc."},{"key":"ref_11","unstructured":"(2026, March 31). FDA Approves Atezolizumab with Chemotherapy and Bevacizumab for First-Line Treatment of Metastatic Non-Squamous NSCLC, Available online: https:\/\/www.fda.gov\/drugs\/fda-approves-atezolizumab-chemotherapy-and-bevacizumab-first-line-treatment-metastatic-non-squamous."},{"key":"ref_12","unstructured":"(2026, March 31). FDA Approves Durvalumab After Chemoradiation for Unresectable Stage III NSCLC, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-durvalumab-after-chemoradiation-unresectable-stage-iii-nsclc."},{"key":"ref_13","unstructured":"(2026, March 31). FDA Approves Atezolizumab with Nab-Paclitaxel and Carboplatin for Metastatic NSCLC Without EGFR\/ALK Aberrations, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-atezolizumab-nab-paclitaxel-and-carboplatin-metastatic-nsclc-without-egfralk."},{"key":"ref_14","unstructured":"(2026, March 31). FDA Approves Nivolumab Plus Ipilimumab for First-Line mNSCLC (PD-L1 Tumor Expression \u22651%), Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nivolumab-plus-ipilimumab-first-line-mnsclc-pd-l1-tumor-expression-1."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1158\/1078-0432.CCR-20-4338","article-title":"FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Non\u2013Small Cell Lung Cancer, A Collaborative Project Orbis Review","volume":"27","author":"Vellanki","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_16","unstructured":"(2026, March 31). FDA Approves Atezolizumab for First-Line Treatment of Metastatic NSCLC with High PD-L1 Expression, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-atezolizumab-first-line-treatment-metastatic-nsclc-high-pd-l1-expression."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1158\/1078-0432.CCR-22-3699","article-title":"FDA Approval Summary: Atezolizumab as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Stage II to IIIA NSCLC","volume":"29","author":"Mathieu","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_18","unstructured":"(2026, March 31). FDA D.I.S.C.O. Burst Edition: Libtayo (Cemiplimab-Rwlc) for First-Line Treatment of Patients with Advanced NSCLC (Locally Advanced Who Are Not Candidates for Surgical Resection or Definitive Chemoradiation or Metastatic) Whose Tumors Have High PD-L1 Expression with No eGFR, Anaplastic Lymphoma Kinase or Receptor Tyrosine Kinase Aberrations, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-disco-burst-edition-libtayo-cemiplimab-rwlc-first-line-treatment-patients-advanced-nsclc-locally."},{"key":"ref_19","unstructured":"(2026, March 31). FDA Approves Cemiplimab-Rwlc in Combination with Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-cemiplimab-rwlc-combination-platinum-based-chemotherapy-non-small-cell-lung-cancer."},{"key":"ref_20","unstructured":"(2026, March 31). FDA Approves Tremelimumab in Combination with Durvalumab and Platinum-Based Chemotherapy for Metastatic Non-Small Cell Lung Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tremelimumab-combination-durvalumab-and-platinum-based-chemotherapy-metastatic-non."},{"key":"ref_21","unstructured":"(2026, March 31). FDA Approves Neoadjuvant Nivolumab and Platinum-Doublet Chemotherapy for Early-Stage Non-Small Cell Lung Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-neoadjuvant-nivolumab-and-platinum-doublet-chemotherapy-early-stage-non-small-cell-lung."},{"key":"ref_22","unstructured":"(2026, March 31). FDA Approves Neoadjuvant\/Adjuvant Pembrolizumab for Resectable Non-Small Cell Lung Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-neoadjuvant-adjuvant-pembrolizumab-resectable-non-small-cell-lung-cancer."},{"key":"ref_23","unstructured":"(2026, March 31). FDA Approves Neoadjuvant\/Adjuvant Durvalumab for Resectable Non-Small Cell Lung Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-neoadjuvantadjuvant-durvalumab-resectable-non-small-cell-lung-cancer."},{"key":"ref_24","unstructured":"(2026, March 31). FDA Approvals in Oncology: October-December 2024, Available online: https:\/\/www.aacr.org\/blog\/2025\/01\/03\/fda-approvals-in-oncology-october-december-2024\/."},{"key":"ref_25","unstructured":"(2026, March 31). FDA Approves Pembrolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-adjuvant-treatment-non-small-cell-lung-cancer."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Leone, G.M., Scuderi, G., Fagone, P., and Mangano, K. (2025). Directions of Immunotherapy for Non-Small-Cell Lung Cancer Treatment: Past, Present and Possible Future. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262211055"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jama.2019.11058","article-title":"Systemic Therapy for Locally Advanced and Metastatic Non\u2013Small Cell Lung Cancer: A Review","volume":"322","author":"Arbour","year":"2019","journal-title":"JAMA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non\u2013Small-Cell Lung Cancer with PD-L1 Tumor Proportion Score of 50% or Greater","volume":"37","author":"Reck","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_29","unstructured":"(2026, March 31). Non-Small Cell Lung Cancer. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1002\/cncr.33142","article-title":"Pembrolizumab plus Chemotherapy versus Chemotherapy Alone in Patients with Advanced Non\u2013Small Cell Lung Cancer without Tumor PD-L1 Expression: A Pooled Analysis of 3 Randomized Controlled Trials","volume":"126","author":"Borghaei","year":"2020","journal-title":"Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1200\/JCO.21.01845","article-title":"Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies","volume":"40","author":"Passaro","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Tuerhong, N., Yang, Y., Feng, J., He, B., Huang, P., Wen, F., and Li, Q. (2026). Comparative Predictive Value of Immunotherapy Biomarkers: A Systematic Review and Network Meta-Analysis. Int. J. Surg.","DOI":"10.1097\/JS9.0000000000004588"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1200\/JCO.23.00059","article-title":"First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2\u2013Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non\u2013Small-Cell Lung Cancer: TROPION-PanTumor01","volume":"41","author":"Shimizu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Kuo, P., Elboudwarej, E., Zavodovskaya, M., Lin, K.-W., Lee, C.V., Diehl, L., Patel, J., Mekan, S., and J\u00fcrgensmeier, J.M. (2025). Trop-2 Expression in Non\u2013Small Cell Lung Cancer. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0321555"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"115161","DOI":"10.1016\/j.colsurfb.2025.115161","article-title":"Antibody-Drug Conjugates (ADCs): \u201cSmart Missiles\u201d Targeting Cancer Therapy","volume":"257","author":"Yao","year":"2026","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"oyaf331","DOI":"10.1093\/oncolo\/oyaf331","article-title":"Antibody Drugs Conjugates in Non\u2013Small Cell Lung Cancer: Current Status and Challenges","volume":"30","author":"Syal","year":"2025","journal-title":"Oncologist"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Van Den Avont, A., and Sharma-Walia, N. (2023). Anti-Nucleolin Aptamer AS1411: An Advancing Therapeutic. Front. Mol. Biosci., 10.","DOI":"10.3389\/fmolb.2023.1217769"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s11912-025-01655-5","article-title":"Targeting Lung Cancer with Precision: The ADC Therapeutic Revolution","volume":"27","author":"Tawfiq","year":"2025","journal-title":"Curr. Oncol. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/oncolo\/oyae151","article-title":"FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for Unresectable or Metastatic Non-Small Cell Lung Cancer with Activating HER2 Mutations","volume":"29","author":"Mehta","year":"2024","journal-title":"Oncologist"},{"key":"ref_40","unstructured":"(2026, February 08). FDA Grants Accelerated Approval to Datopotamab Deruxtecan-Dlnk for EGFR-Mutated Non-Small Cell Lung Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-datopotamab-deruxtecan-dlnk-egfr-mutated-non-small-cell-lung-cancer."},{"key":"ref_41","unstructured":"(2026, February 08). FDA Grants Accelerated Approval to Telisotuzumab Vedotin-Tllv for NSCLC with High c-Met Protein Overexpression, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-telisotuzumab-vedotin-tllv-nsclc-high-c-met-protein-overexpression."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12943-023-01751-9","article-title":"New Frontiers in Immune Checkpoint B7-H3 (CD276) Research and Drug Development","volume":"22","author":"Getu","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"S744","DOI":"10.1016\/j.annonc.2022.07.582","article-title":"453O DS-7300 (B7-H3 DXd Antibody-Drug Conjugate [ADC]) Shows Durable Antitumor Activity in Advanced Solid Tumors: Extended Follow-up of a Phase I\/II Study","volume":"33","author":"Doi","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1080\/13543784.2025.2512566","article-title":"Clinical Progress of B7-H3 Targeted Antibody Drug Conjugate Ifinatamab Deruxtecan for Small-Cell Lung Cancer","volume":"34","author":"Wespiser","year":"2025","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1200\/JCO.2025.43.16_suppl.3036","article-title":"Results from a Phase 1\/2 Study of 7MW3711: A Novel B7-H3 Antibody-Drug Conjugate (ADC) Incorporating a Topoisomerase I Inhibitor in Patients with Lung Cancer","volume":"43","author":"Li","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"53","DOI":"10.36401\/JIPO-23-18","article-title":"B7-H3 Inhibitors in Oncology Clinical Trials: A Review","volume":"7","author":"Feustel","year":"2024","journal-title":"J. Immunother. Precis. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/s41591-025-03600-2","article-title":"A B7H3-Targeting Antibody\u2013Drug Conjugate in Advanced Solid Tumors: A Phase 1\/1b Trial","volume":"31","author":"Ma","year":"2025","journal-title":"Nat. Med."},{"key":"ref_48","unstructured":"(2025, October 25). Duality Biologics Duality Biologics and BioNTech Presented Positive Interim Data for Investigational B7-H3 Antibody-Drug Conjugate BNT324\/DB-1311 in Advanced Solid Tumors at the ESMO Asia Congress 2024. Available online: https:\/\/www.biospace.com\/press-releases\/duality-biologics-and-biontech-presented-positive-interim-data-for-investigational-b7-h3-antibody-drug-conjugate-bnt324-db-1311-in-advanced-solid-tumors-at-the-esmo-asia-congress-2024."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Majumder, A. (2023). HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of Cancer. Cells, 12.","DOI":"10.3390\/cells12212517"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1200\/JCO.2024.42.16_suppl.3034","article-title":"YL202\/BNT326, a HER3-Targeted ADC, in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Breast Cancer: Preliminary Results from a First-in-Human Phase I Trial","volume":"42","author":"Cheng","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.2025.43.16_suppl.3000","article-title":"DB-1310, a HER3-Targeted ADC, in Pts with Advanced Solid Tumors: Preliminary Results from the Phase 1\/2a Trial","volume":"43","author":"Lisberg","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_52","unstructured":"(2025, October 25). BioNTech BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update. Available online: https:\/\/www.globenewswire.com\/news-release\/2024\/08\/05\/2924129\/0\/en\/BioNTech-Announces-Second-Quarter-2024-Financial-Results-and-Corporate-Update.html."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.2340\/1651-226X.2025.44344","article-title":"Prevalence, Molecular Characterization, and Prognosis of c-Met Protein Overexpression in a Real-World Cohort of Patients with Non-Squamous Non-Small Cell Lung Cancer","volume":"64","author":"Bar","year":"2025","journal-title":"Acta Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1002\/cncr.33159","article-title":"The METeoric Rise of MET in Lung Cancer","volume":"126","author":"Friedlaender","year":"2020","journal-title":"Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2025.43.16_suppl.106","article-title":"Phase 1 Study of SHR-1826, a c-MET\u2013Directed Antibody-Drug-Conjugate (ADC), in Advanced Solid Tumors","volume":"43","author":"Zhang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"8613","DOI":"10.1200\/JCO.2025.43.16_suppl.8613","article-title":"MYTX-011, a cMET-Targeting Antibody-Drug Conjugate (ADC), in Patients with Previously Treated, Advanced NSCLC: Updated Dose Escalation Results in the Phase 1 KisMET-01 Study","volume":"43","author":"Heist","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1200\/JCO.2025.43.16_suppl.3025","article-title":"A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced\/Metastatic Solid Tumors","volume":"43","author":"Wang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_58","unstructured":"(2025, October 25). The Updated Clinical Results for PD-L1 ADC HLX43 at the 2025 WCLC, Demonstrate Outstanding Efficacy in NSCLC. Available online: https:\/\/www.henlius.com\/en\/NewsDetails-5441-26.html."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"8611","DOI":"10.1200\/JCO.2025.43.16_suppl.8611","article-title":"Interim Results of PDL1V (PF-08046054), a Vedotin-Based ADC Targeting PD-L1, in Patients with NSCLC in a Phase 1 Trial","volume":"43","author":"Fontana","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific Antibodies: A Mechanistic Review of the Pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s40291-024-00734-w","article-title":"Clinical Progresses and Challenges of Bispecific Antibodies for the Treatment of Solid Tumors","volume":"28","author":"Gu","year":"2024","journal-title":"Mol. Diagn. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Ma, J., Mo, Y., Tang, M., Shen, J., Qi, Y., Zhao, W., Huang, Y., Xu, Y., and Qian, C. (2021). Bispecific Antibodies: From Research to Clinical Application. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.626616"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The Making of Bispecific Antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"mAbs"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymeth.2018.08.010","article-title":"Building Blocks for Bispecific and Trispecific Antibodies","volume":"154","author":"Wu","year":"2019","journal-title":"Methods"},{"key":"ref_65","unstructured":"(2026, February 14). FDA Approves Bispecific Antibody Plus Chemotherapy for EGFR Exon 20 Insertion\u2013Mutated NSCLC. Available online: https:\/\/jnccn360.org\/non-small-cell-lung-cancer\/news\/fda-approves-bispecific-antibody-plus-chemotherapy-for-egfr-exon-20-insertion-mutated-nsclc\/?utm_source=chatgpt.com."},{"key":"ref_66","unstructured":"(2026, February 14). New Bispecific Antibody Granted Approval in NSCLC Harboring NRG1 Gene Fusion. Available online: https:\/\/jnccn360.org\/non-small-cell-lung-cancer\/news\/new-bispecific-antibody-granted-approval-in-nsclc-harboring-nrg1-gene-fusion\/?utm_source=chatgpt.com."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"5030","DOI":"10.1158\/1078-0432.CCR-21-2390","article-title":"Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy","volume":"28","author":"Andrews","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Chocarro, L., Bocanegra, A., Blanco, E., Fern\u00e1ndez-Rubio, L., Arasanz, H., Echaide, M., Garnica, M., Ramos, P., Pi\u00f1eiro-Hermida, S., and Vera, R. (2022). Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor. Cells, 11.","DOI":"10.3390\/cells11152351"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Sauer, N., Szlasa, W., Jonderko, L., O\u015bliz\u0142o, M., Kunachowicz, D., Kulbacka, J., and Kar\u0142owicz-Bodalska, K. (2022). LAG-3 as a Potent Target for Novel Anticancer Therapies of a Wide Range of Tumors. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23179958"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Piekarz, J., Picheta, N., Szklener, K., and Ma\u0144dziuk, S. (2025). TIGIT Expression and Its Implications in Non-Small-Cell Lung Cancer Progression and Therapy: A Systematic Review. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26199307"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1200\/JCO.2025.43.16_suppl.2641","article-title":"First-in-Human Study of ZGGS15, a Dual-Specific Antibody Targeting LAG-3 and TIGIT, as Monotherapy in Patients with Advanced Solid Tumors","volume":"43","author":"Zhu","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1200\/JCO.2025.43.16_suppl.2610","article-title":"Combination of Bispecific Innate Cell Engager (ICE) AFM24 with Atezolizumab in Patients with Advanced\/Metastatic Non-Small Cell Lung Cancer (NSCLC) with EGFR Kinase Domain Mutations (EGFR Mut): Initial Results from a Phase 2a Study","volume":"43","author":"Saavedra","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1200\/JCO.2025.43.16_suppl.2609","article-title":"Bispecific Innate Cell Engager (ICE) AFM24 in Combination with Atezolizumab in Patients with Advanced\/Metastatic EGFR-Expressing Non-Small Cell Lung Cancer (NSCLC) without Driver Mutations: Initial Results from a Phase 2a Study","volume":"43","author":"Kim","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"8509","DOI":"10.1200\/JCO.2025.43.16_suppl.8509","article-title":"First-in-Class PD-1\/IL-2 Bispecific Antibody IBI363 in Patients (Pts) with Advanced Immunotherapy-Treated Non-Small Cell Lung Cancer (NSCLC)","volume":"43","author":"Zhou","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"8570","DOI":"10.1200\/JCO.2025.43.16_suppl.8570","article-title":"SMET12 and Toripalimab Combined Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer Who Are Treatment-Naive or Have Developed Resistance to Standard Therapy","volume":"43","author":"Lin","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jama.2023.24735","article-title":"Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non\u2013Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial","volume":"331","author":"Lu","year":"2024","journal-title":"JAMA"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1200\/JCO.22.00727","article-title":"Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non\u2013Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1016\/j.cell.2024.03.039","article-title":"IGSF8 Is an Innate Immune Checkpoint and Cancer Immunotherapy Target","volume":"187","author":"Li","year":"2024","journal-title":"Cell"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1200\/JCO.2025.43.16_suppl.2531","article-title":"Preliminary Monotherapy Efficacy of Novel Immune Checkpoint Blockade GV20-0251 (Anti-IGSF8) in Advanced Melanoma Patients with Primary Resistance to Anti-PD1","volume":"43","author":"Wentzel","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.semcancer.2025.12.002","article-title":"Microbiota and Cancer Immunotherapy: Mechanisms, Clinical Implications, and Precision Therapeutics","volume":"118","author":"Wei","year":"2026","journal-title":"Semin. Cancer Biol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Duttagupta, S., Messaoudene, M., Hunter, S., Desilets, A., Jamal, R., Mihalcioiu, C., Belkaid, W., Marcoux, N., Fidelle, M., and Suissa, D. (2026). Fecal Microbiota Transplantation plus Immunotherapy in Non-Small Cell Lung Cancer and Melanoma: The Phase 2 FMT-LUMINate Trial. Nat. Med.","DOI":"10.1038\/s41591-025-04186-5"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13578-023-01135-y","article-title":"The Impact of the Gut Microbiome on Tumor Immunotherapy: From Mechanism to Application Strategies","volume":"13","author":"Guo","year":"2023","journal-title":"Cell Biosci."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13045-018-0592-6","article-title":"Gut Microbiome Modulates Efficacy of Immune Checkpoint Inhibitors","volume":"11","author":"Yi","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1200\/JCO-25-00374","article-title":"Microbiome Modulation for the Treatment of Solid Neoplasms","volume":"43","author":"Zengin","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/s41573-025-01211-7","article-title":"The Gut Microbiome as a Target in Cancer Immunotherapy: Opportunities and Challenges for Drug Development","volume":"24","author":"Elkrief","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"11504","DOI":"10.1038\/s41598-017-12016-z","article-title":"Pan-Genomic and Transcriptomic Analyses of Leuconostoc mesenteroides Provide Insights into Its Genomic and Metabolic Features and Roles in Kimchi Fermentation","volume":"7","author":"Chun","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/s00403-024-03324-2","article-title":"Exploring the Therapeutic Potential of Leuconostoc mesenteroides Lysates in Wound Healing and Immune Modulation on Keratinocyte Cells","volume":"316","author":"Altves","year":"2024","journal-title":"Arch. Dermatol. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.biopha.2017.08.033","article-title":"Leuconostoc mesenteroides-Derived Anticancer Pharmaceuticals Hinder Inflammation and Cell Survival in Colon Cancer Cells by Modulating NF-\u03baB\/AKT\/PTEN\/MAPK Pathways","volume":"94","author":"Barzegari","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s11274-024-04018-7","article-title":"Upregulation of Immune Checkpoint PD-L1 in Colon Cancer Cell Lines and Activation of T Cells by Leuconostoc mesenteroides","volume":"40","author":"Altves","year":"2024","journal-title":"World J. Microbiol. Biotechnol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"8547","DOI":"10.1200\/JCO.2025.43.16_suppl.8547","article-title":"First-in-Human Study of CJRB-101, a Live Biotherapeutic Product in Combination with Pembrolizumab in Selected Types of Advanced or Metastatic Cancer","volume":"43","author":"Lee","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_91","unstructured":"(2025, December 02). EXL01 in the Clinic. Available online: https:\/\/www.exeliombio.com\/pipeline\/exl01-s-description-clinical-trials."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","article-title":"Tumor-Infiltrating Lymphocyte Treatment for Anti-PD-1-Resistant Metastatic Lung Cancer: A Phase 1 Trial","volume":"27","author":"Creelan","year":"2021","journal-title":"Nat. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00262-020-02735-0","article-title":"Chimeric Antigen Receptor (CAR)-T-Cell Therapy in Non-Small-Cell Lung Cancer (NSCLC): Current Status and Future Perspectives","volume":"70","author":"Qu","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Khalaf, K., Hana, D., Chou, J.T.-T., Singh, C., Mackiewicz, A., and Kaczmarek, M. (2021). Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.656364"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/978-3-319-91287-5_27","article-title":"Hypoxia-\/HIF-1\u03b1-Driven Factors of the Tumor Microenvironment Impeding Antitumor Immune Responses and Promoting Malignant Progression","volume":"Volume 1072","author":"Thews","year":"2018","journal-title":"Oxygen Transport to Tissue XL"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41577-021-00541-y","article-title":"Metabolic Barriers to Cancer Immunotherapy","volume":"21","author":"DePeaux","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"106939","DOI":"10.1016\/j.intimp.2020.106939","article-title":"Effects of Immune Cells and Cytokines on Inflammation and Immunosuppression in the Tumor Microenvironment","volume":"88","author":"Li","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e2317283121","DOI":"10.1073\/pnas.2317283121","article-title":"Tumor Resistance to Anti-Mesothelin CAR-T Cells Caused by Binding to Shed Mesothelin Is Overcome by Targeting a Juxtamembrane Epitope","volume":"121","author":"Liu","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1038\/s41467-019-11869-4","article-title":"CXCR1- or CXCR2-Modified CAR T Cells Co-Opt IL-8 for Maximal Antitumor Efficacy in Solid Tumors","volume":"10","author":"Jin","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Doeppner, C.A., Binder, A.K., Bremm, F., Feuchter, N., D\u00f6rrie, J., and Schaft, N. (2025). Rendering NK Cells Antigen-Specific for the Therapy of Solid Tumours. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26136290"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s12026-025-09726-2","article-title":"Efficacy and Safety of Natural Killer Cell Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer: A Meta-Analysis and Systematic Review","volume":"73","author":"Li","year":"2025","journal-title":"Immunol. Res."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Jansen, K., Kornfeld, L., Lennartz, M., Dwertmann Rico, S., Kind, S., Reiswich, V., Viehweger, F., Bawahab, A.A., Fraune, C., and Gorbokon, N. (2024). Carcinoembryonic Antigen Expression in Human Tumors: A Tissue Microarray Study on 13,725 Tumors. Cancers, 16.","DOI":"10.3390\/cancers16234052"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"107356","DOI":"10.1016\/j.lungcan.2023.107356","article-title":"The Search for Therapeutic Targets in Lung Cancer: Preclinical and Human Studies of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 Expression and Its Associated Molecular Landscape","volume":"184","author":"Lefebvre","year":"2023","journal-title":"Lung Cancer"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.athoracsur.2004.02.009","article-title":"Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease","volume":"78","author":"Okada","year":"2004","journal-title":"Ann. Thorac. Surg."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"8517","DOI":"10.1200\/JCO.2025.43.16_suppl.8517","article-title":"Hypoxia-Responsive CEA CAR-T Cells Therapy for Relapsed or Refractory Non-Small Cell Lung Cancer: A Single-Arm, Open-Label, Phase I Trial","volume":"43","author":"Wei","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e186890","DOI":"10.1172\/jci.insight.186890","article-title":"Interim Report on Engineered NK Cell Trial in Lung Cancer Refractory to Immune Checkpoint Inhibitors","volume":"10","author":"Tian","year":"2025","journal-title":"JCI Insight"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1158\/2159-8290.CD-18-1259","article-title":"The Mechanism of Anti\u2013PD-L1 Antibody Efficacy against PD-L1\u2013Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector","volume":"9","author":"Dong","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Bai, R., and Cui, J. (2022). Burgeoning Exploration of the Role of Natural Killer Cells in Anti-PD-1\/PD-L1 Therapy. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.886931"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s11912-023-01367-8","article-title":"Targeting Mesothelin in Solid Tumours: Anti-Mesothelin Antibody and Drug Conjugates","volume":"25","author":"Chu","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Molina, J., Tokatlian, T., Wang, J., Sharma, S., Manry, D., Naradikian, M., Asuelime, G., DiAndreth, B., Winters, A., and Miguel, T.S. (2022). 263 A2B694, an Autologous Logic-Gated Cell Therapy Targeting Mesothelin. Proceedings of the Regular and Young Investigator Award Abstracts, BMJ Publishing Group Ltd.","DOI":"10.1136\/jitc-2022-SITC2022.0263"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Punekar, S.R., Ward, J., Park, J.C., Patel, S.P., Maloney, D., Dorigo, O., Kirtane, K., Marcela, M., Morelli, M.P., and Lou, Y. (June, January 30). EVEREST-2: Initial Data of the Logic-gated Tmod Chimeric Antigen Receptor T-cell (CAR T) Therapy A2B694 for Patients with Solid Tumors Associated with Mesothelin (MSLN) Expression and with Human Leukocyte Antigen (HLA) Loss of Heterozygosity (LOH). Proceedings of the 2025 ASCO Annual Meeting, Chicago, IL, USA.","DOI":"10.1200\/JCO.2025.43.16_suppl.3040"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1200\/JCO.2025.43.16_suppl.3040","article-title":"EVEREST-2: Initial Data of the Logic-Gated Tmod Chimeric Antigen Receptor T-Cell (CAR T) Therapy A2B694 for Patients with Solid Tumors Associated with Mesothelin (MSLN) Expression and with Human Leukocyte Antigen (HLA) Loss of Heterozygosity (LOH)","volume":"43","author":"Punekar","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Dziadziuszko, R., Deme, D., Ramlau, R., G\u00f6ker, E., Yalcin, B., Munshi, N., Markman, J.L., Chen, V., Rout, M.K., and Dalle Fratte, C. (2025). Abstract CT013: Phase I Trial Evaluating BNT116, a TAA-Encoding mRNA Vaccine, in Combination with Cemiplimab in Frail Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). Cancer Res., 85.","DOI":"10.1158\/1538-7445.AM2025-CT013"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"\u00d6ven, B.B., Baz, D.V., Wolf, J., Ates, O., G\u00f6ker, E., Br\u00fcck, P., Wenger, M., Munshi, N., Tsyhankova, I., and Tsyhankova, I. (2024). Abstract CT051: Preliminary Results from LuCa-MERIT-1, a First-in-Human Phase I Trial Evaluating the Fixed Antigen mRNA Vaccine BNT116 + Docetaxel in Patients with Advanced Non-Small Cell Lung Cancer. Cancer Res., 84.","DOI":"10.1158\/1538-7445.AM2024-CT051"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Atmaca, A., Alt, J., Baz, D.V., Dziadziuszko, R., Moreno, V., Pose, V., Juan-Vidal, O., Munshi, N., Markman, J.L., and Chen, V. (2024). 1486 Preliminary Results from LuCa-MERIT-1, a Phase I Trial Evaluating BNT116, a Fixed Antigen mRNA Vaccine, plus Cemiplimab in Advanced Non-Small Cell Lung Cancer after Progression on PD-1 Inhibition. Proceedings of the Late-Breaking Abstracts, BMJ Publishing Group Ltd.","DOI":"10.1136\/jitc-2024-SITC2024.1486"},{"key":"ref_116","unstructured":"(2025, December 03). Anti PD1\/IL-15 Fusion Protein SAR445877, Available online: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-drug\/def\/anti-pd1-il-15-fusion-protein-sar445877."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Pratumchai, I., Bernardo, M., Marquardt, K.L., Zhu, C., Menas, F., Carrio, R., Byers, T., Shaffer, D., Li, X., and Teijaro, J.R. (2024). Abstract 4063: SAR445877, an Anti-PD-1 Antibody-IL-15 Mutein Fusion Protein Restores Function to Exhausted T Cells. Cancer Res., 84.","DOI":"10.1158\/1538-7445.AM2024-4063"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1200\/JCO.2025.43.16_suppl.2572","article-title":"Initial Safety and Efficacy Results from a First-in-Human, Phase 1\/2 Study of SAR445877, an Anti-PD-1\/IL-15 Fusion Protein, for Patients with Advanced Solid Tumors","volume":"43","author":"Naing","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1200\/JCO.2025.43.16_suppl.2575","article-title":"Inhaled KB707, a Novel HSV-Based Immunotherapy, as a Monotherapy in Patients with Advanced Solid Tumor Malignancies Affecting the Lungs: Efficacy and Safety Results from a Phase 1\/2 Study","volume":"43","author":"Ma","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1200\/JCO.2025.43.16_suppl.2589","article-title":"Phase 1 Study of DK210 (EGFR), a Tumor-Targeted IL2 x IL10 Dual Immunocytokine, in Advanced Cancer Patients: Dose Escalation, Immune Activation, and Safety Results","volume":"43","author":"Spira","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_121","unstructured":"(2025, October 27). Tissue Expression of NECTIN4\u2014Summary\u2014The Human Protein Atlas. Available online: https:\/\/www.proteinatlas.org\/ENSG00000143217-NECTIN4\/tissue."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e000266","DOI":"10.1136\/jitc-2019-000266","article-title":"Nectin4 Is a Novel TIGIT Ligand Which Combines Checkpoint Inhibition and Tumor Specificity","volume":"8","author":"Reches","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/14712598.2021.1929168","article-title":"Targeting Nectin-4 by Antibody-Drug Conjugates for the Treatment of Urothelial Carcinoma","volume":"21","author":"Wong","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_124","unstructured":"Sathekge, M. (2026, March 31). New \u2018Mini-Protein\u2019 Carries Radiation Dose Directly to Tumours Without Harming Healthy Tissues. Available online: https:\/\/event.eortc.org\/ena2024\/2024\/10\/25\/new-mini-protien-radiation-dose\/."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.ejca.2024.114539","article-title":"AKY-1189, a Novel, First-in-Class Miniprotein Radiopharmaceutical Designed to Deliver Actinium-225 (225Ac) to Nectin-4 Expressing Tumors with Broad Therapeutic Applications in Metastatic Urothelial Carcinoma (mUC) and Other Nectin-4 Expressing Tumors","volume":"211","author":"Sathekge","year":"2024","journal-title":"Eur. J. Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/8\/1291\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T07:31:44Z","timestamp":1776670304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/8\/1291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,19]]},"references-count":125,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["cancers18081291"],"URL":"https:\/\/doi.org\/10.3390\/cancers18081291","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,19]]}}}